Antisense antibacterial method and compound
A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication. The compound binds to a target mRNA with a T m of between 50° to 60° C. The relatively short antisense compounds are substantially more active than conventional antisense compounds having a targeting base sequence of 15 or more bases.
1. A method of inhibiting the growth of pathogenic bacterial cells, comprising
exposing the bacterial cells to a growth-inhibiting amount of a substantially uncharged antisense oligonucleotide compound
of 10 to 12 bases in length having a targeting sequence of at least 10 bases that are complementary to a target sequence containing or within 10 bases downstream of the translational start codon of a bacterial mRNA that encodes a bacterial protein selected from the group consisting of acyl carrier protein (acpP), gyrase A subunit (gyrA), and the cell division protein ftsZ, wherein the antisense oligonucleotide compound
is a morpholino antisense oligonucleotide.
2. The method of claim 1 , wherein the morpholino subunits of the antisense oligonucleotide compound are joined by phosphorus-containing linkages, in accordance with the structure:
where Y 1 ═O, Z═O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, amino or alkyl amino, including dialkylamino.
3. The method of claim 1 , wherein the targeting sequence is complementary to a target sequence containing the translational start codon of the bacterial mRNA.
4. The method of claim 1 , wherein the targeting sequence is complementary to a target sequence that is within 10 bases downstream of the translational start codon of the bacterial mRNA.
5. The method of claim 1 , wherein the antisense oligonucleotide compound contains 11 bases, and has a nucleic acid sequence that is completely complementary to the mRNA target sequence.
6. The method of claim 1 , for use in inhibiting a bacterial infection in a mammalian subject, wherein said exposing includes administering the antisense oligonucleotide compound in a therapeutically effective amount.
7. The method of claim 6 , further comprising the step of treating the subject by administration of a non-antisense compound having antibacterial activity.
8. A substantially uncharged antisense oligonucleotide compound
of 10 to 12 bases in length having a targeting sequence of at least 10 bases that are complementary to a target sequence containing or within 10 bases downstream of the translational start codon of a bacterial mRNA that encodes a bacterial protein selected from the group consisting of acyl carrier protein (acpP), gyrase A subunit (gyrA), and the cell division protein ftsZ, wherein the antisense oligonucleotide compound
is a morpholino antisense oligonucleotide.
9. The antisense oligonucleotide compound of claim 8 , wherein the bacterial mRNA encodes the ftsZ protein, and the targeting sequence is complementary to at least ten contiguous bases in a sequence selected from the group consisting of SEQ ID NOS: 1, 4, 7, 10, 13, 16, 19, 22, 27, 30, 33, 38, 41, 44, 47, 50, 53, and 56.
10. The antisense oligonucleotide compound of claim 8 , wherein the bacterial mRNA encodes the acpP protein, and the targeting sequence is complementary to at least ten contiguous bases in a sequence selected from the group consisting of SEQ ID NOS: 2, 5, 8, 11, 14, 17, 23, 28, 31, 34, 36, 39, 42, 45, 48, 51, 54, and 57.
11. The antisense oligonucleotide compound of claim 8 , wherein the bacterial mRNA encodes the gyrA protein, and the targeting sequence is complementary to at least ten contiguous bases in a sequence selected from the group consisting of SEQ ID NOS: 3, 6, 9, 12, 15, 18, 20, 24, 29, 32, 35, 37, 40, 43, 46, 49, 52, 55, and 58.
12. The antisense oligonucleotide compound of claim 8 , wherein the morpholino subunits of the antisense oligonucleotide compound are joined by phosphorus-containing linkages, in accordance with the structure:
where Y 1 ═O, Z═O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, amino or alkyl amino, including dialkylamino.
13. The antisense oligonucleotide compound of claim 8 , wherein the targeting sequence is complementary to a target sequence containing the translational start codon of the bacterial mRNA.
14. The antisense oligonucleotide compound of claim 8 , wherein the targeting sequence is complementary to a target sequence that is within 10 bases downstream of the translational start codon of the bacterial mRNA.
15. The antisense oligonucleotide compound of claim 8 , which contains 11 bases, and has a nucleic acid sequence that is completely complementary to the mRNA target sequence.
16. The antisense oligonucleotide compound of claim 8 , which contains 10 bases, and has a nucleic acid sequence that is completely complementary to the mRNA target sequence.
17. The method of claim 1 , wherein the bacterial mRNA encodes the ftsZ protein, and the targeting sequence is complementary to at least ten contiguous bases in a sequence selected from the group consisting of SEQ ID NOS: 1, 4, 7, 10, 13, 16, 19, 22, 27, 30, 33, 38, 41, 44, 47, 50, 53, and 56.
18. The method of claim 1 , wherein the bacterial mRNA encodes the acpP protein, and the targeting sequence is complementary to at least ten contiguous bases in a sequence selected from the group consisting of SEQ ID NOS: 2, 5, 8, 11, 14, 17, 23, 28, 31, 34, 36, 39, 42, 45, 48, 51, 54, and 57.
19. The method of claim 1 , wherein the bacterial mRNA encodes the gyrA protein, and the targeting sequence is complementary to at least ten contiguous bases in a sequence selected from the group consisting of SEQ ID NOS: 3, 6, 9, 12, 15, 18, 20, 24, 29, 32, 35, 37, 40, 43, 46, 49, 52, 55, and 58.
20. The method of claim 2 , wherein the phosphorus-containing linkages are phosphorodiamidate linkages.
21. The method of claim 20 , wherein each X is NR 2 wherein each R is CH 3 .
22. The method of claim 2 , wherein up to one of every five phosphorus-containing linkages is positively charged, wherein X is 1-piperazine.
23. The antisense oligonucleotide compound of claim 12 , wherein the phosphorus-containing linkages are phosphorodiamidate linkages.
24. The antisense oligonucleotide compound of claim 23 , wherein each X is NR 2 wherein each R is CH 3 .
25. The antisense oligonucleotide compound of claim 12 , wherein up to one of every five phosphorus-containing linkages is positively charged, wherein X is 1-piperazine.
26. An antisense oligonucleotide of 11 nucleotide bases for inhibiting the growth of pathogenic bacterial cells comprising a base sequence of CTTCGATAGTG (SEQ ID NO: 109) that is completely complementary to a bacterial mRNA that encodes the acyl carrier protein (acpP), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide.
27. The antisense oligonucleotide of claim 26 , wherein the antisense oligonucleotide is conjugated to a polyethylene glycol moiety.
28. An antisense oligonucleotide of 10 nucleotide bases for inhibiting the growth of pathogenic bacterial cells comprising a base sequence of TTCGATAGTG (SEQ ID NO: 110) that is completely complementary to a bacterial mRNA that encodes the acyl carrier protein (acpP), wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide.
29. The antisense oligonucleotide of claim 28 , wherein the antisense oligonucleotide is conjugated to a polyethylene glycol moiety.